|
WO2020077297A1
|
|
Methods and compositions for treatment of protein aggregation-based disorders
|
|
CA3093922A1
|
|
Methods and compositions for treatment of polyglucosan disorders
|
|
CN109963576A
|
|
For treating the method and composition of Lafora disease
|
|
AU2015308894A1
|
|
Internalizing moieties for treatment of cancer
|
|
TW201618809A
|
|
Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
|
|
US2017130216A1
|
|
Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
|
|
AU2015204446A1
|
|
Internalizing moieties
|
|
CA2901969A1
|
|
Methods and compositions for treatment of forbes-cori disease
|
|
CN105189542A
|
|
Methods and compositions for treatment of pompe disease
|
|
US2014178377A1
|
|
Methods and compositions for treatment of myotonic dystrophy
|
|
US2015152170A1
|
|
Methods for increasing muscle contractility
|
|
CA2907072A1
|
|
Antisense conjugates for decreasing expression of dmpk
|
|
AU2010260145A1
|
|
Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
|
